Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 ΔV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin

Vaccine

Volumn 26, Issue 9, 2008, Pages 1214-1227

  Caputo, Antonella ^a   Brocca Cofano, Egidio ^a   Castaldello, Arianna ^a   Voltan, Rebecca ^a   Gavioli, Riccardo ^b   Srivastava, Indresh K ^c   Barnett, Susan W ^c   Cafaro, Aurelio ^d   Ensoli, Barbara ^d  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c MS X 600A   (United States)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

HIV 1 gp140 V2Env; HIV 1 Tat; LTK63; Mice; Mucosal vaccine; SIV Gag

Indexed keywords

ADJUVANT; ESCHERICHIA COLI ENTEROTOXIN; GAG PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 140; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 4; NEUTRALIZING ANTIBODY; TRANSACTIVATOR PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; SPLEEN CELL; STATISTICAL ANALYSIS; WESTERN BLOTTING;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; AIDS VACCINES; ANIMALS; BACTERIAL TOXINS; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; FEMALE; GENE PRODUCTS, GAG; GENE PRODUCTS, TAT; GLYCOPROTEINS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, MUCOSAL; MICE; MICE, INBRED BALB C; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES; VACCINATION;

EID: 39149119252     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.12.030     Document Type: Article

References (79)

1. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5 3 (2004) 233-236
2. Cohen J. Clinical research. A setback and an advance on the AIDS vaccine front. Science 300 5616 (2003) 28-29
3. Richardson Jr. T.M., Stryjewski B.L., Broder C.C., Hoxie J.A., Mascola J.R., Earl P.L., et al. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein. J Virol 70 2 (1996) 753-762
4. Yang X., Wyatt R., and Sodroski J. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J Virol 75 3 (2001) 1165-1171
5. Buckner C., Gines L.G., Saunders C.J., Vojtech L., Srivastava I., Gettie A., et al. Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV. Virology 320 1 (2004) 167-180
6. Cherpelis S., Srivastava I., Gettie A., Jin X., Ho D.D., Barnett S.W., et al. DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques. J Virol 75 3 (2001) 1547-1550
7. Zolla-Pazner S. Improving on nature: focusing the immune response on the V3 loop. Hum Antibodies 14 3/4 (2005) 69-72
8. Burton D.R., Stanfield R.L., and Wilson I.A. Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci U S A 102 42 (2005) 14943-14948
9. Kwong P.D., Doyle M.L., Casper D.J., Cicala C., Leavitt S.A., Majeed S., et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420 6916 (2002) 678-682
10. Wyatt R., and Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280 5371 (1998) 1884-1888
11. Barnett S.W., Lu S., Srivastava I., Cherpelis S., Gettie A., Blanchard J., et al. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 75 12 (2001) 5526-5540
12. Srivastava I.K., Stamatatos L., Kan E., Vajdy M., Lian Y., Hilt S., et al. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. J Virol 77 20 (2003) 11244-11259
13. Srivastava I.K., VanDorsten K., Vojtech L., Barnett S.W., and Stamatatos L. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J Virol 77 4 (2003) 2310-2320
14. Barnett S.W., Srivastava I.K., Ulmer J.B., Donnelly J.J., and Rappuoli R. Development of V2-deleted trimeric envelope vaccine candidates from human immunodeficiency virus type 1 (HIV-1) subtypes B and C. Microbes Infect 7 14 (2005) 1386-1391
15. Letvin N.L. Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol 6 12 (2006) 930-939
16. Titti F., Cafaro A., Ferrantelli F., Tripiciano A., Moretti S., Caputo A., et al. Problems and emerging approaches in HIV/AIDS vaccine development. Expert Opin Emerg Drugs 12 1 (2007) 23-48
17. Ferrantelli F., Cafaro A., and Ensoli B. Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines. Curr Opin Biotechnol 15 6 (2004) 543-556
18. Caputo A., Gavioli R., and Ensoli B. Recent advances in the development of HIV-1 Tat-based vaccines. Curr HIV Res 2 4 (2004) 357-376
19. Ensoli B. Rational vaccine strategies against AIDS: background and rationale. Microbes Infect 7 14 (2005) 1445-1452
20. Ensoli B. Criteria for selection of HIV vaccine candidates-general principles. Microbes Infect 7 14 (2005) 1433-1435
21. Ensoli B. Introduction: rational vaccine strategies against AIDS. Microbes Infect 7 14 (2005) 1385
22. Ensoli B., Cafaro A., Caputo A., Fiorelli V., Ensoli F., Gavioli R., et al. Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env. Microbes Infect 7 14 (2005) 1392-1399
23. Borsutzky S., Ebensen T., Link C., Becker P.D., Fiorelli V., Cafaro A., et al. Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant. Vaccine 24 12 (2006) 2049-2056
24. Cafaro A., Caputo A., Fracasso C., Maggiorella M.T., Goletti D., Baroncelli S., et al. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med 5 6 (1999) 643-650
25. Cafaro A., Titti F., Fracasso C., Maggiorella M.T., Baroncelli S., Caputo A., et al. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine 19 20-22 (2001) 2862-2877
26. Maggiorella M.T., Baroncelli S., Michelini Z., Fanales-Belasio E., Moretti S., Sernicola L., et al. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. Vaccine 22 25/26 (2004) 3258-3269
27. Rezza G., Fiorelli V., Dorrucci M., Ciccozzi M., Tripiciano A., Scoglio A., et al. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. J Infect Dis 191 8 (2005) 1321-1324
28. van Baalen C.A., Pontesilli O., Huisman R.C., Geretti A.M., Klein M.R., de Wolf F., et al. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol 78 Pt 8 (1997) 1913-1918
29. Butto S., Fiorelli V., Tripiciano A., Ruiz-Alvarez M.J., Scoglio A., Ensoli F., et al. Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans. J Infect Dis 188 8 (2003) 1171-1180
30. Ensoli B., Fiorelli V., Ensoli F., Cafaro A., Titti F., Butto S., et al. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. Aids 20 18 (2006) 2245-2261
31. Fanales-Belasio E., Moretti S., Nappi F., Barillari G., Micheletti F., Cafaro A., et al. Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses. J Immunol 168 1 (2002) 197-206
32. Gavioli R., Gallerani E., Fortini C., Fabris M., Bottoni A., Canella A., et al. HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity. J Immunol 173 6 (2004) 3838-3843
33. Kittiworakarn J., Lecoq A., Moine G., Thai R., Lajeunesse E., Drevet P., et al. HIV-1 Tat raises an adjuvant-free humoral immune response controlled by its core region and its ability to form cysteine-mediated oligomers. J Biol Chem 281 6 (2006) 3105-3115
34. Gavioli R, Cellini S, Castaldello A, Voltan R, Gallerani E, Gagliardoni F, et al. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccines against AIDS. Vaccine 2008;26(5):727-37.
35. Haase A.T. Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 5 10 (2005) 783-792
36. Stevceva L., and Strober W. Mucosal HIV vaccines: where are we now?. Curr HIV Res 2 1 (2004) 1-10
37. Yuki Y., Nochi T., and Kiyono. Porgress towards an AIDS mucosal vaccine: an overview. Tubercolosis 87 (2007) S35-S44
38. Veazey R.S., and Lackner A.A. HIV swiftly guts the immune system. Nat Med 11 5 (2005) 469-470
39. Cassetti M.C., McElhiney S.P., Shahabi V., Pullen J.K., Le Poole I.C., Eiben G.L., et al. Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine 22 3/4 (2004) 520-527
40. Gluck U., Gebbers J.O., and Gluck R. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J Virol 73 9 (1999) 7780-7786
41. Hashigucci K., Ogawa H., Ishidate T., Yamashita R., Kamiya H., Watanabe K., et al. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine 14 2 (1996) 113-119
42. Yuki Y., and Kiyono H. New generation of mucosal adjuvants for the induction of protective immunity. Rev Med Virol 13 (2003) 293-310
43. Peppoloni S., Ruggiero P., Contorni M., Morandi M., Pizza M., Rappuoli R., et al. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev Vaccines 2 2 (2003) 285-293
44. Xu Y, Zhang H, Xu X. Enhancement of vaccine potency by fusing modified LTK63 into human papillomavirus tpe 16 chimeric virus-like particles. FEMS Immunol Med Microbiol 2008;52(1):99-109.
45. Tempesta M., Camero M., Bellacicco A.L., Tarsitano E., Lorusso A., Martella V., et al. Caprine herpesvirus 1 vaccine with the LTK63 mutant as a mucosal adjuvant induces strong protection against genital infection in goats. Vaccine 25 46 (2007) 7929-7930
46. Tritto E., Muzzi A., Pesce I., Monaci E., Nuti S., Galli G., et al. The acquired immune response to the mucosal adjuvant LTK63 imprints the mouse lung with a protective signature. J Immunol 179 8 (2007) 5346-5357
47. O'Hagan D.T. Recent advances in immunological adjuvants: the development of particulate antigen delivery systems. Expert Opin Investig Drugs 7 3 (1998) 349-359
48. Stephenson I., Zambon M.C., Rudin A., Colegate A., Podda A., Bugarini R., et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol 80 10 (2006) 4962-4970
49. Ensoli B., Buonaguro L., Barillari G., Fiorelli V., Gendelman R., Morgan R.A., et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 67 1 (1993) 277-287
50. Stamatatos L., and Cheng-Mayer C. An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades. J Virol 72 10 (1998) 7840-7845
51. Otten G., Schaefer M., Greer C., Calderon-Cacia M., Coit D., Kazzaz J., et al. Induction of broad and potent anti-human immunodeficiency virus immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylactide coglycolide microparticles. J Virol 77 10 (2003) 6087-6092
52. Di Tommaso A., Saletti G., Pizza M., Rappuoli R., Dougan G., Abrignani S., et al. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect Immun 64 3 (1996) 974-979
53. Rappuoli R., Pizza M., Douce G., and Dougan G. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol Today 20 11 (1999) 493-500
54. Pizza M., Giuliani M.M., Fontana M.R., Monaci E., Douce G., Dougan G., et al. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19 17-19 (2001) 2534-2541
55. Castaldello A., Brocca-Cofano E., Voltan R., Triulzi C., Altavilla G., Laus M., et al. DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination. Vaccine 24 29/30 (2006) 5655-5669
56. Ramakrishna L., Anand K.K., Mohankumar K.M., and Ranga U. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization. J Virol 78 17 (2004) 9174-9189
57. Karlsson G.B., Halloran M., Li J., Park I.W., Gomila R., Reimann K.A., et al. Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys. J Virol 71 6 (1997) 4218-4225
58. Brave A., Hinkula J., Cafaro A., Eriksson L.E., Srivastava I.K., Magnani M., et al. Candidate HIV-1 gp140ΔV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge. Vaccine 25 (2007) 6882-6890
59. Rollman E., Mathy N., Bråve A., Boberg A., Kjerrström A., van Wely C., et al. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model. Vaccine 25 11 (2007) 2145-2154
60. Voltan R., Castaldello A., Brocca-Cofano E., Altavilla G., Caputo A., Laus M., et al. Preparation and characterization of innovative protein-coated poly(methylmethacrylate) core-shell nanoparticles for vaccine purposes. Pharm Res 24 10 (2007) 1870-1882
61. Horner A.A., Sandip K.D., Takabayashi K., Belyakov I.M., Hayashi T., Cinman N., et al. Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites. J Immunol 167 (2001) 1584-1591
62. Hoffmann D., Seebach J., Cosma A., Goebel F.D., Strimmer K., Schatzl H.S., et al. Therapeutic vaccination reduces HIV sequence variability. FASEB J 22 (2008) 437-444
63. Ensoli B. AIDS Vaccine Integrated Project (AVIP): a novel program and developing countries partnership. Bioforum Europe 9 (2005) 38-40
64. Becker P.D., Fiorentini S., Link C., Tosti G., Ebensen T., Caruso A., et al. The HIV-1 matrix protein p17 can be efficiently delivered by intranasal route in mice using the TL2/6 agonist MALP-2 as mucosal adjuvant. Vaccine 24 (2006) 5269-5376
65. Munro P., Flatau G., and Lemichez E. Intranasal immunization with tetanus toxoid and CNF1 as new mucosal adjuvant protects Balb/c mice against lethal challenge. Vaccine 25 (2007) 8702-8706
66. Hel Z., Tsai W.P., Tryniszewska E., Nacsa J., Markham P.D., Lewis M.G., et al. Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes. J Immunol 176 1 (2006) 85-96
67. Mooij P., Nieuwenhuis I.G., Knoop C.J., Doms R.W., Bogers W.M., Ten Haaft P.J., et al. Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection. J Virol 78 7 (2004) 3333-3342
68. Zhao J., Voltan R., Peng B., Davis-Warren A., Kalyanaraman V.S., Alvord W.G., et al. Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag. Virology 342 1 (2005) 1-12
69. Shu Y., Winfrey S., Yang Z.Y., Xu L., Rao S.S., Srivastava I., et al. Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. Vaccine 25 8 (2007) 1398-1408
70. Ferrantelli F., and Ruprecht R.M. Neutralizing antibodies against HIV -back in the major leagues?. Curr Opin Immunol 14 (2002) 1271-1290
71. Masoìcola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6 (2000) 207-210
72. Nishimura Y., Igarashi T., Haigwood N.L., Sadjadpour R., Doanu O.K., Buckler C., et al. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implication for HIV-1 vaccine development. Proc Natl Acad Sci USA 100 (2003) 15131-15136
73. Holl V., Peressin M., Decoville T., Schmidt S., Zolla-Pazner S., Aubertin A.M., et al. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type q replication in macrophages and immature dendritic cells. J Virol 80 (2006) 6177-6181
74. Arquaro S., Calio R., Balzarini J., Bellocchi M.C., Garaci E., and Perno C.F. Macrophages and HIV infection: therapeutical approaches toward this strategic virus resevoir. Antivir Res 55 (2002) 209-225
75. Larsson M. HIV-1 and the hijacking of dendritic cells: a tug of war. Springer Semin Immunopathol 26 (2005) 309-328
76. Peng B., Wang L.R., Gomez-Roman V.R., Davis-Warren A., Montefiori D.C., Kalyanaraman V.S., et al. Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies. J Virol 79 16 (2005) 10200-10209
77. Gomez-Roman V.R., Florese R.H., Peng B., Montefiori D.C., Kalyanaraman V.S., Venzon D., et al. An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains. J Acquir Immune Defic Syndr 43 3 (2006) 270-277
78. Belyakov I.M., Hel Z., Kelsall B., Kuznetsov V.A., Ahlers J.D., Nacsa J., et al. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med 7 12 (2001) 1320-1326
79. Vajdy M. Induction of optimal immune responses against human immunodeficiency virus at mucosal portals of entry. Curr Drug Targets Immune Endocr Metabol Disord 3 3 (2003) 222-233